An Italian multicenter prospective observational cohort study assessing the 2-year rate of switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL
Latest Information Update: 30 Jul 2021
At a glance
- Drugs HIV integrase inhibitors (Primary) ; HIV protease inhibitors (Primary) ; Non-nucleoside reverse transcriptase inhibitors (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 30 Jul 2021 New trial record